Pulmonx reports trial results for emphysema treatment system
Pulmonx (LUNG) reported CONVERT Trial results for its AeriSeal System in severe emphysema patients, showing 75.8% success in converting collateral ventilation status. Treated patients achieved 88.9% target lobe volume reduction at 45 days, with improvements in lung function and quality of life. The company is enrolling patients in the CONVERT II Pivotal Trial for U.S. FDA approval.
How this was made
The 30-second read
Why it matters
The publication of CONVERT Trial results provides concrete efficacy endpoints and supports the rationale for ongoing CONVERT II enrollment and the planned US PMA application timeline.
Market read
For LUNG, the key trading relevance is the newly published efficacy endpoints that strengthen the evidence narrative ahead of CONVERT II and the FDA PMA submission.
What to watch
Traders may discount the impact if the article does not include safety/tolerability details, durability beyond 12 months, or comparative performance versus existing collateral-ventilation assessment approaches.
Background
Pulmonx is evaluating the AeriSeal System to identify and convert collateral ventilation status in severe emphysema patients, with Zephyr Endobronchial Valves used after successful conversion.
Ticker impact
Pulmonx published CONVERT Trial results for its AeriSeal System, reporting 75.8% conversion to collateral ventilation negative status and subsequent Zephyr valve outcomes.
Likely upward bias as traders price improved probability of regulatory progress and clearer patient-selection benefit for Zephyr valve therapy.
The article discloses specific trial endpoints (conversion rate and 45-day/12-month lobe volume reduction) and ties them to the planned PMA support timeline, which can move biotech/device sentiment even without an approval decision.
Market effects
Reinforces the broader endobronchial valve ecosystem’s emphasis on collateral ventilation assessment and patient-selection, potentially affecting sentiment across lung-device peers.
Limited direct regional read-through; trial sites are Europe and Australia but the commercial/regulatory pathway is US-focused.
Moderate global relevance for interventional pulmonology, mainly through evidence quality and regulatory-readiness signals.
Counterpoint
Published results may not change near-term valuation if investors already expected CONVERT data, and the key remaining catalyst is CONVERT II and FDA PMA acceptance rather than publication alone.
Key entities
- companyPulmonx Corporation
NASDAQ-listed medical device company developing the AeriSeal System and Zephyr Endobronchial Valves for severe emphysema.
- productAeriSeal System
Device evaluated in the CONVERT Trial to convert collateral ventilation positive lobes to collateral ventilation negative status.
- productZephyr Endobronchial Valves
Valves used after AeriSeal conversion to achieve target lobe volume reduction.
- clinical_studyCONVERT Trial
101-patient, 14-site Europe and Australia trial published in Respiration: International Journal of Thoracic Medicine.
- clinical_studyCONVERT II Pivotal Trial
Ongoing multicenter study designed to enroll about 200 patients to support a US PMA application, with six-month results intended for FDA support.

